

- **Name:** **Mathew J. Garnett**
  - **Current Position & Affiliation:** **Senior Faculty Member,  
Wellcome Sanger Institute**
  - **Country:** **UK**
- 

- **Educational Background:**

Doctor of Philosophy | The Institute of Cancer Research | 2000 - 2004

Oncogene signaling and mutations of BRAF in human cancer

Supervisor: Prof. Richard Marais

Bachelor of Science | University of British Columbia, Canada | 1995 - 1999

Biochemistry Honours

Research Project: Genetic analysis of childhood cancers

- **Professional Experience:**

Senior Faculty Member | Wellcome Sanger Institute | 2014 – current

Translational Cancer Genomics lab (<https://www.sanger.ac.uk/science/groups/garnett-group>).

Senior Staff Scientist | Wellcome Sanger Institute | 2009 – 2014

Drug screens in cancer cells to identify molecular determinants of sensitivity

Postdoctoral Scientist | University of Cambridge | 2004 - 2009

Regulation of mitosis and chromosomal instability in cancer

Supervisor: Prof. Ashok Venkitaraman

- **Professional Organizations:**

Nature Webcast | Applications of Organoids 2019

Panel Member (co-opted) | Wellcome Trust Grant Interview Panel 2019

Management Committee | AZ-CRUK Functional Genomics Centre 2019 - current

Panel Member | Acad. of Medical Sciences: annual FORUM lecture on CRISPR 2019

Invited Speaker | Royal Society: 'The CRISPR Revolution: Changing Life'. 2018

Consultant | Sanofi Pharmaceuticals – lecture on precision medicine 2018

Governance Board | Human Cancer Model Initiative 2017 - current

Innovation Board | Milner Therapeutics Consortium, Cambridge 2014 - current

Open Targets Leadership Team | Sanger Representative 2014 - current

CRUK Drug Discovery Small Molecule Expert Review Panel 2014 - 2019

Organiser | WT Conf. on Cancer Pharmacogenomics and Targeted Therapies 2013, 2014

- **Main Scientific Publications:**

\*equal contribution | ^corresponding author

Total number of publications: 70

Total number of first author publications: 7

Total number of senior author publication: 16

For publication with >100 citations, the number is indicated (17 of 70; updated Jan 2020)

Direct team members names are in bold font (since forming my own research team and excluding core facility staff)

Picco G\*, Chen ED\*, Alonso LG, Behan FM, Gonçalves E, Bignell G, Matchan A, Fu B, Banerjee R, Anderson E, Butler A, Benes CH, McDermott U, Dow D, Iorio F, Stronach E, Yang F, Yusa K, Saez-Rodriguez J, **Garnett MJ**<sup>^</sup>. Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening. Nat Commun. 2019 May 16;10(1):2198. doi: 10.1038/s41467-019-09940-1. PMID: 31097696; PMCID: PMC6522557.

Behan FM\*, Iorio F\*, Picco G\*, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K<sup>^</sup>, **Garnett MJ**<sup>^</sup>.  
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019 Apr; 568(7753): 511-516. PMID: 30971826.